U.S. patent application number 12/437159 was filed with the patent office on 2009-08-27 for omp p6 vaccine for treating and preventing chlamydia infection.
This patent application is currently assigned to SANOFI PASTEUR LIMITED. Invention is credited to Pamela Dunn, Andrew D. Murdin, Raymond P. Oomen, Joe Wang.
Application Number | 20090214639 12/437159 |
Document ID | / |
Family ID | 22624065 |
Filed Date | 2009-08-27 |
United States Patent
Application |
20090214639 |
Kind Code |
A1 |
Murdin; Andrew D. ; et
al. |
August 27, 2009 |
OMP P6 VACCINE FOR TREATING AND PREVENTING CHLAMYDIA INFECTION
Abstract
The present invention provides a vaccine for immunization of a
host, including humans, against disease caused by infection by a
strain of Chlamydia, specifically C. pneumoniae. The vaccine
contains a polypeptide comprising an omp P6 precursor sequence of a
strain of C. pneumoniae and variants of the sequence. Modifications
are possible within the scope of this invention.
Inventors: |
Murdin; Andrew D.; (Richmond
Hill, CA) ; Oomen; Raymond P.; (Aurora, CA) ;
Wang; Joe; (Toronto, CA) ; Dunn; Pamela;
(Woodbridge, CA) |
Correspondence
Address: |
SMART & BIGGAR;P.O. BOX 2999, STATION D
900-55 METCALFE STREET
OTTAWA
ON
K1P 5Y6
CA
|
Assignee: |
SANOFI PASTEUR LIMITED
Toronto
ON
|
Family ID: |
22624065 |
Appl. No.: |
12/437159 |
Filed: |
May 7, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11070478 |
Mar 3, 2005 |
|
|
|
12437159 |
|
|
|
|
10334137 |
Dec 31, 2002 |
7019125 |
|
|
11070478 |
|
|
|
|
09747348 |
Dec 22, 2000 |
|
|
|
10334137 |
|
|
|
|
60171525 |
Dec 22, 1999 |
|
|
|
Current U.S.
Class: |
424/450 ;
424/190.1; 514/1.1 |
Current CPC
Class: |
A61K 48/00 20130101;
C07K 2319/02 20130101; Y02A 50/476 20180101; A61K 39/00 20130101;
A61K 2039/53 20130101; A61P 31/04 20180101; A61K 2039/505 20130101;
Y02A 50/30 20180101; C07K 2319/00 20130101; C07K 14/295 20130101;
A61K 38/164 20130101 |
Class at
Publication: |
424/450 ; 514/12;
424/190.1 |
International
Class: |
A61K 9/127 20060101
A61K009/127; A61K 38/16 20060101 A61K038/16; A61K 39/02 20060101
A61K039/02 |
Claims
1. A method for preventing or treating Chlamydia infection
comprising the step of administering a composition comprising a
protein and an adjuvant, wherein the protein comprises the amino
acid sequence set forth in SEQ ID No:2.
2. The method according to claim 1 wherein the protein is a fusion
protein comprising the amino acid sequence fused with a
heterologous polypeptide.
3. The method according to claim 2 wherein the heterologous
polypeptide is a peptide tail for purifying the protein.
4. The method according to claim 1 wherein the adjuvant is a
liposome.
5. The method according to claim 4 wherein the liposome is at least
one liposome selected from the group consisting of neutral
liposomes, anionic liposomes, microspheres, ISCOMS, and
virus-like-particles (VLPs).
6. The method according to claim 1 wherein the composition is
administered parenterally.
7. The method according to claim 6 wherein the adjuvant is at least
one adjuvant selected from the group consisting of an aluminum
compound, RIBI, polyphosphazene, DC-chol (3 b-(N--(N',N'-dimethyl
aminomethane)-carbamoyl) cholesterol) and QS-21.
8. The method according to claim 7 wherein the adjuvant is aluminum
hydroxide, aluminum phosphate, or aluminum hydroxy phosphate.
9. The method according to claim 1 wherein the composition is
administered mucosally.
10. The method according to claim 9 wherein the adjuvant is at
least one adjuvant selected from the group consisting of bacterial
toxin, bacterial monophosphoryl lipid A (MPLA), saponin,
polylactide glycolide (PLGA) microsphere, polyphosphazene, DC-chol
(3 b-(N--(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol), and
QS-21.
11. The method according to claim 10 wherein the adjuvant is at
least one bacterial toxin selected from the group consisting of
cholera toxin (CT), E. coli heat-labile toxin (LT), Clostridium
difficile toxin A, pertussis toxin (PT), and combinations,
subunits, toxoids, or mutants thereof that retain adjuvant activity
and/or have reduced toxicity.
12. The method according to claim 11 wherein the adjuvant is at
least one bacterial toxin selected from the group consisting of
native cholera toxin subunit B (CTB), Arg-7-Lys CT mutant,
Arg-192-Gly LT mutant, Arg-9-Lys PT mutant, Glu-129-Gly PT mutant,
Ser-63-Lys LT mutant, Ala-69-Gly LT mutant, Glu-110-Asp LT mutant,
and Glu-112-Asp LT mutant.
13. The method according to claim 10 wherein the adjuvant is
bacterial monophosphoryl lipid A (MPLA) of E. coli, Salmonella
minnesota, Salmonella typhimurium, or Shigella flexneri.
14. The method according to claim 1 wherein the composition is in
unit dosage form.
15. The method according to claim 1 wherein the composition is
administered as a priming dose and a booster dose.
16. The method according to claim 1 wherein the composition is
administered as a booster dose in conjunction with a vaccine vector
encoding and expressing the amino acid sequence set forth in SEQ ID
NO:2.
17. The method according to claim 1 wherein the composition is
administered at less than 1 mg per dose.
18. The method according to claim 1 wherein the composition is
administered at 100 .mu.g per dose.
19. The method according to claim 1 wherein the composition is
administered at 10 .mu.g to 500 mg per dose.
20. The method according to claim 1 wherein the composition is
administered at 1 mg to 200 mg per dose.
21. The method according to claim 16 wherein the composition is
administered as a booster dose mucosally at 10 .mu.g to 500 mg per
dose.
22. The method according to claim 16 wherein the composition is
administered as a booster dose mucosally at 1 mg to 200 mg per
dose.
Description
REFERENCE TO RELATED APPLICATIONS
[0001] This is a divisional of U.S. patent application Ser. No.
11/070,478 filed Mar. 3, 2005, which is a divisional of U.S. patent
application Ser. No. 10/334,137 filed Dec. 31, 2002, now U.S. Pat.
No. 7,019,125, which is a continuation of U.S. patent application
Ser. No. 09/747,348 filed Dec. 22, 2000, now abandoned, which
claims the benefit of U.S. Provisional Application No. 60/171,525,
filed Dec. 22, 1999, the contents of which are herein incorporated
by reference.
FIELD OF INVENTION
[0002] The present invention relates to the Chlamydia OMP P6
precursor and corresponding DNA molecules, which can be used to
prevent and treat Chlamydia infection in mammals, such as
humans.
BACKGROUND OF THE INVENTION
[0003] Chlamydiae are prokaryotes. They exhibit morphologic and
structural similarities to gram-negative bacteria including a
trilaminar outer membrane, which contains lipopolysaccharide and
several membrane proteins that are structurally and functionally
analogous to proteins found in E coli. They are obligate
intra-cellular parasites with a unique biphasic life cycle
consisting of a metabolically inactive but infectious extracellular
stage and a replicating but non-infectious intracellular stage. The
replicative stage of the life-cycle takes place within a
membrane-bound inclusion which sequesters the bacteria away from
the cytoplasm of the infected host cell.
[0004] C. pneumoniae is a common human pathogen, originally
described as the TWAR strain of Chlamydia psittaci but subsequently
recognised to be a new species. C. pneumoniae is antigenically,
genetically and morphologically distinct from other chlamydia
species (C. trachomatis, C. pecorum and C. psittaci). It shows 10%
or less DNA sequence homology with either of C. trachomatis or C.
psittaci.
[0005] C. pneumoniae is the third most common cause of community
acquired pneumonia, only less frequent than Streptococcus
pneumoniae and Mycoplasma pneumoniae (Grayston et al. (1995)
Journal of Infectious Diseases 168:1231; Campos et al. (1995)
Investigation of Opthalmology and Visual Science 36:1477). It can
also cause upper respiratory tract symptoms and disease, including
bronchitis and sinusitis (Grayston et al. (1995) Journal of
Infectious Diseases 168:1231; Grayston et al (1990) Journal of
Infectious Diseases 161:618-625; Marrie (1993) Clinical Infectious
Diseases. 18:501-513; Wang et al (1986) Chlamydial infections
Cambridge University Press, Cambridge. p. 329. The great majority
of the adult population (over 60%) has antibodies to C. pneumoniae
(Wang et al (1986) Chlamydial infections. Cambridge University
Press, Cambridge. p. 329), indicating past infection which was
unrecognized or asymptomatic.
[0006] C. pneumoniae infection usually presents as an acute
respiratory disease (i.e., cough, sore throat, hoarseness, and
fever; abnormal chest sounds on auscultation). For most patients,
the cough persists for 2 to 6 weeks, and recovery is slow. In
approximately 10% of these cases, upper respiratory tract infection
is followed by bronchitis or pneumonia. Furthermore, during a C.
pneumoniae epidemic, subsequent co-infection with pneumococcus has
been noted in about half of these pneumonia patients, particularly
in the infirm and the elderly. As noted above, there is more and
more evidence that C. pneumoniae infection is also linked to
diseases other than respiratory infections.
[0007] The reservoir for the organism is presumably people. In
contrast to C. psittaci infections, there is no known bird or
animal reservoir. Transmission has not been clearly defined. It may
result from direct contact with secretions, from fomites, or from
airborne spread. There is a long incubation period, which may last
for many months. Based on analysis of epidemics, C. pneumoniae
appears to spread slowly through a population (case-to-case
interval averaging 30 days) because infected persons are
inefficient transmitters of the organism. Susceptibility to C.
pneumoniae is universal. Reinfections occur during adulthood,
following the primary infection as a child. C. pneumoniae appears
to be an endemic disease throughout the world, noteworthy for
superimposed intervals of increased incidence (epidemics) that
persist for 2 to 3 years. C. trachomatis infection does not confer
cross-immunity to C. pneumoniae. Infections are easily treated with
oral antibiotics, tetracycline or erythromycin (2 g/d, for at least
10 to 14 d). A recently developed drug, azithromycin, is highly
effective as a single-dose therapy against chlamydial
infections.
[0008] In most instances, C. pneumoniae infection is often mild and
without complications, and up to 90% of infections are subacute or
unrecognized. Among children in industrialized countries,
infections have been thought to be rare up to the age of 5 y,
although a recent study (E Normann et al, Chlamydia pneumoniae in
children with acute respiratory tract infections, Acta Paediatrica,
1998, Vol 87, Iss 1, pp 23-27) has reported that many children in
this age group show PCR evidence of infection despite being
seronegative, and estimates a prevalence of 17-19% in 2-4 y olds.
In developing countries, the seroprevalence of C. pneumoniae
antibodies among young children is elevated, and there are
suspicions that C. pneumoniae may be an important cause of acute
lower respiratory tract disease and mortality for infants and
children in tropical regions of the world.
[0009] From seroprevalence studies and studies of local epidemics,
the initial C. pneumoniae infection usually happens between the
ages of 5 and 20 y. In the USA, for example, there are estimated to
be 30,000 cases of childhood pneumonia each year caused by C.
pneumoniae. Infections may cluster among groups of children or
young adults (e.g., school pupils or military conscripts).
[0010] C. pneumoniae causes 10 to 25% of community-acquired lower
respiratory tract infections (as reported from Sweden, Italy,
Finland, and the USA). During an epidemic, C. pneumonia infection
may account for 50 to 60% of the cases of pneumonia. During these
periods, also, more episodes of mixed infections with S. pneumoniae
have been reported.
[0011] Reinfection during adulthood is common; the clinical
presentation tends to be milder. Based on population seroprevalence
studies, there tends to be increased exposure with age, which is
particularly evident among men. Some investigators have speculated
that a persistent, asymptomatic C. pneumoniae infection state is
common.
[0012] In adults of middle age or older, C. pneumoniae infection
may progress to chronic bronchitis and sinusitis. A study in the
USA revealed that the incidence of pneumonia caused by C.
pneumoniae in persons younger than 60 years is 1 case per 1,000
persons per year; but in the elderly, the disease incidence rose
three-fold. C. pneumoniae infection rarely leads to
hospitalization, except in patients with an underlying illness.
[0013] Of considerable importance is the association of
atherosclerosis and C. pneumoniae infection. There are several
epidemiological studies showing a correlation of previous
infections with C. pneumoniae and heart attacks, coronary artery
and carotid artery disease (Saikku et al. (1988) Lancet;
ii:983-986; Thom et al. (1992) JAMA 268:68-72; Linnanmaki et al.
(1993), Circulation 87:1030; Saikku et al. (1992) Annals Internal
Medicine 116:273-287; Melnick et al (1993) American Journal of
Medicine 95:499). Moreover, the organisms has been detected in
atheromas and fatty streaks of the coronary, carotid, peripheral
arteries and aorta (Shor et al. (1992) South African. Medical
Journal 82:158-161; Kuo et al. (1993) Journal of Infectious
Diseases 167:841-849; Kuo et al. (1993) Arteriosclerosis and
Thrombosis 13:1501-1504; Campbell et al (1995) Journal of
Infectious Diseases 172:585; Chiu et al. Circulation, 1997.
Circulation. 96:2144-2148). Viable C. pneumoniae has been recovered
from the coronary and carotid artery (Ramirez et al (1996) Annals
of Internal Medicine 125:979-982; Jackson et al. 1997. J. Infect.
Dis. 176:292-295). Furthermore, it has been shown that C.
pneumoniae can induce changes of atherosclerosis in a rabbit model
(Fong et al. 1997. Journal of Clinical Microbiolology 35:48 and
Laitinen et al. 1997. Infect. Immun. 65:4832-4835). Taken together,
these results indicate that it is highly probable that C.
pneumoniae can cause atherosclerosis in humans, though the
epidemiological importance of chlamydial atherosclerosis remains to
be demonstrated.
[0014] A number of recent studies have also indicated an
association between C. pneumoniae infection and asthma. Infection
has been linked to wheezing, asthmatic bronchitis, adult-onset
asthma and acute exacerbations of asthma in adults, and small-scale
studies have shown that prolonged antibiotic treatment was
effective at greatly reducing the severity of the disease in some
individuals (Hahn D L, et al. Evidence for Chlamydia pneumoniae
infection in steroid-dependent asthma. Ann Allergy Asthma Immunol.
1998 January; 80(1): 45-49; Hahn D L, et al. Association of
Chlamydia pneumoniae IgA antibodies with recently symptomatic
asthma. Epidemiol Infect. 1996 December; 117(3): 513-517; Bjornsson
E, et al. Serology of chlamydia in relation to asthma and bronchial
hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69; Hahn D
L. Treatment of Chlamydia pneumoniae infection in adult asthma: a
before-after trial. J Fam Pract. 1995 October; 41(4): 345-351;
Allegra L, et al. Acute exacerbations of asthma in adults: role of
Chlamydia pneumoniae infection. Eur Respir J. 1994 December; 7(12):
2165-2168; Hahn D L, et al. Association of Chlamydia pneumoniae
(strain TWAR) infection with wheezing, asthmatic bronchitis, and
adult-onset asthma. JAMA. 1991 Jul. 10; 266(2): 225-230).
[0015] In light of these results a protective vaccine against C.
pneumoniae infection would be of considerable importance. There is
not yet an effective vaccine for any human chlamydial infection. It
is conceivable that an effective vaccine can be developed using
physically or chemically inactivated Chlamydiae. However, such a
vaccine does not have a high margin of safety. In general, safer
vaccines are made by genetically manipulating the organism by
attenuation or by recombinant means. Accordingly, a major obstacle
in creating an effective and safe vaccine against human chlamydial
infection has been the paucity of genetic information regarding
Chlamydia, specifically C. pneumoniae.
[0016] Studies with C. trachomatis and C. psittaci indicate that
safe and effective vaccine against Chlamydia is an attainable goal.
For example, mice which have recovered from a lung infection with
C. trachomatis are protected from infertility induced by a
subsequent vaginal challenge (Pal et al. (1996) Infection and
Immunity. 64:5341). Similarly, sheep immunized with inactivated C.
psittaci were protected from subsequent chlamydial-induced
abortions and stillbirths (Jones et al. (1995) Vaccine 13:715). In
a mouse model, protection from chlamydial infections has been
associated with Th1 immune responses, particularly CD8+ CTL
response (Rottenberg et al. 1999. J. Immunol. 162:2829-2836 and
Penttila et al. 1999. Immunology. 97:490-496) and it is unlikely
that similar responses will need to be induced in humans to confer
protection. However, antigens able to elicit a protective immune
response against C. pneumoniae are largely unknown. The presence of
sufficiently high titres of neutralising antibody at mucosal
surfaces can also exert a protective effect (Cotter et al. (1995)
Infection and Immunity 63:4704).
[0017] Antigenic variation within the species C. pneumoniae is not
well documented due to insufficient genetic information, though
variation is expected to exist based on C. trachomatis. Serovars of
C. trachomatis are defined on the basis of antigenic variation in
the major outer membrane protein (MOMP), but published C.
pneumoniae MOMP gene sequences show no variation between several
diverse isolates of the organism (Campbell et al. Infection and
Immunity (1990) 58:93; McCafferty et al Infection and Immunity
(1995) 63:2387-9; Gaydos et al. Infection and Immunity. (1992)
60(12):5319-5323). The gene encoding a 76 kDa antigen has been
cloned from a single strain of C. pneumoniae and the sequence
published (Perez Melgosa et al. Infection and Immunity. (1994)
62:880). An operon encoding the 9 kDa and 60 kDa cysteine-rich
outer membrane protein genes has been described (Watson et al.,
Nucleic Acids Res (1990) 18:5299; Watson et al., Microbiology
(1995) 141:2489). Many antigens recognized by immune sera to C.
pneumoniae are conserved across all chlamydiae, but 98 kDa, 76 kDa
and several other proteins may be C. pneumoniae-specific (Knudsen
et al. Infect. Immun. 1999. 67:375-383; Perez Melgosa et al.
Infection and Immunity. 1994. 62:880; Melgosa et al., FEMS
Microbiol Lett 1993. 112 :199; Campbell et al., J. Clin. Microbiol.
1990. 28 :1261; Iijima et al., J. Clin. Microbiol. 1994. 32:583).
Antisera to 76 kDa and 54 kDa antigens have been reported to
neutralize C. pneumoniae in vitro (Perez Melgosa et al. 1994.
Infect. Immun. 62:880-886 and Wiedman-Al-Ahmad et al. 1997. Clin.
Diagn. Lab. Immunol. 4:700-704). An assessment of the number and
relative frequency of any C. pneumoniae serotypes, and the defining
antigens, is not yet possible. The entire genome sequence of C.
pneumoniae strain CWL-029 is now known and as further sequences
become available a better understanding of antigenic variation may
be gained.
[0018] Many antigens recognised by immune sera to C. pneumoniae are
conserved across all chlamydiae, but 98 kDa, 76 kDa and 54 kDa
proteins appear to be C. pneumoniae-specific (Campos et al. (1995)
Investigation of Opthalmology and Visual Science 36:1477; Marrie
(1993) Clinical Infectious Diseases. 18:501-513; Wiedmann-Al-Ahmad
M, et al. Reactions of polyclonal and neutralizing anti-p54
monoclonal antibodies with an isolated, species-specific
54-kilodalton protein of Chlamydia pneumoniae. Clin Diagn Lab
Immunol. 1997 November; 4(6): 700-704).
[0019] Immunoblotting of isolates with sera from patients does show
variation of blotting patterns between isolates, indicating that
serotypes C. pneumoniae may exist (Grayston et al. (1995) Journal
of Infectious Diseases 168:1231; Ramirez et al (1996) Annals of
Internal Medicine 125:979-982). However, the results are
potentially confounded by the infection status of the patients,
since immunoblot profiles of a patient's sera change with time
post-infection. An assessment of the number and relative frequency
of any serotypes, and the defining antigens, is not yet
possible.
[0020] The use of DNA immunization to elicit a protective immune
response in Balb/c mice against pulmonary infection with the mouse
pneumonitis (MoPn) strain of Chlamydia trachomatis has recently
been described (Zhang et al. 1997. J. Infect. Dis. 76:1035-1040 and
Zhang et al. 1999. Immunology. 96:314-321).
[0021] Accordingly, a need exists for identifying and isolating
polynucleotide sequences of C. pneumoniae for use in preventing and
treating Chlamydia infection.
SUMMARY OF THE INVENTION
[0022] The present invention provides purified and isolated
polynucleotide molecules that encode the Chlamydia polypeptides
designated omp P6 precursor gene product (SEQ ID No: 1) which can
be used in methods to prevent, treat, and diagnose Chlamydia
infection. In one form of the invention, the polynucleotide
molecules are DNA that encode the polypeptide of SEQ ID No: 2.
[0023] Another form of the invention provides polypeptides
corresponding to the isolated DNA molecules. The amino acid
sequence of the corresponding encoded polypeptide is shown as SEQ
ID No: 2.
[0024] Those skilled in the art will readily understand that the
invention, having provided the polynucleotide sequences encoding
the Chlamydia omp P6 precursor, also provides polynucleotides
encoding fragments derived from such a polypeptide. Moreover, the
invention is understood to provide mutants and derivatives of such
polypeptides and fragments derived therefrom, which result from the
addition, deletion, or substitution of non-essential amino acids as
described herein. Those skilled in the art would also readily
understand that the invention, having provided the polynucleotide
sequences encoding Chlamydia polypeptides, further provides
monospecific antibodies that specifically bind to such
polypeptides.
[0025] The present invention has wide application and includes
expression cassettes, vectors, and cells transformed or transfected
with the polynucleotides of the invention. Accordingly, the present
invention further provides (i) a method for producing a polypeptide
of the invention in a recombinant host system and related
expression cassettes, vectors, and transformed or transfected
cells; (ii) a vaccine, or a live vaccine vector such as a pox
virus, Salmonella typhimurium, or Vibrio cholerae vector,
containing a polynucleotide of the invention, such vaccines and
vaccine vectors being useful for, e.g., preventing and treating
Chlamydia infection, in combination with a diluent or carrier, and
related pharmaceutical compositions and associated therapeutic
and/or prophylactic methods; (iii) a therapeutic and/or
prophylactic use of an RNA or DNA molecule of the invention, either
in a naked form or formulated with a delivery vehicle, a
polypeptide or combination of polypeptides, or a monospecific
antibody of the invention, and related pharmaceutical compositions;
(iv) a method for diagnosing the presence of Chlamydia in a
biological sample, which can involve the use of a DNA or RNA
molecule, a monospecific antibody, or a polypeptide of the
invention; and (v) a method for purifying a polypeptide of the
invention by antibody-based affinity chromatography.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The present invention will be further understood from the
following description with reference to the drawings, in which:
[0027] FIGS. 1A and 1B show the nucleotide sequence of the omp P6
precursor gene (SEQ ID No: 1) and the deduced amino acid sequence
of the omp P6 precursor gene product from Chlamydia pneumoniae (SEQ
ID No: 2).
[0028] FIGS. 2A, 2B and 2C show the restriction enzyme analysis of
the C. pneumoniae omp P6 precursor gene.
[0029] FIG. 3 shows the construction and elements of plasmid
pCABk831.
[0030] FIG. 4 illustrates protection against C. pneumoniae
infection by pCABk831 following DNA immunization.
DETAILED DESCRIPTION OF INVENTION
[0031] An open reading frame (ORF) encoding the Chlamydial omp P6
precursor has been identified from the C. pneumoniae genome. The
gene encoding this protein has been inserted into an expression
plasmid and shown to confer immune protection against chlamydial
infection. Accordingly, this omp P6 precursor and related
polypeptides can be used to prevent and treat Chlamydia
infection.
[0032] According to a first aspect of the invention, isolated
polynucleotides are provided which encode Chlamydia polypeptides,
whose amino acid sequences are shown in SEQ ID No: 2.
[0033] The term "isolated polynucleotide" is defined as a
polynucleotide removed from the environment in which it naturally
occurs. For example, a naturally-occurring DNA molecule present in
the genome of a living bacteria or as part of a gene bank is not
isolated, but the same molecule separated from the remaining part
of the bacterial genome, as a result of, e.g., a cloning event
(amplification), is isolated. Typically, an isolated DNA molecule
is free from DNA regions (e.g., coding regions) with which it is
immediately contiguous at the 5' or 3' end, in the naturally
occurring genome. Such isolated polynucleotides may be part of a
vector or a composition and still be defined as isolated in that
such a vector or composition is not part of the natural environment
of such polynucleotide.
[0034] The polynucleotide of the invention is either RNA or DNA
(cDNA, genomic DNA, or synthetic DNA), or modifications, variants,
homologs or fragments thereof. The DNA is either double-stranded or
single-stranded, and, if single-stranded, is either the coding
strand or the non-coding (anti-sense) strand. Any one of the
sequences that encode the polypeptides of the invention as shown in
SEQ ID No: 1 is (a) a coding sequence, (b) a ribonucleotide
sequence derived from transcription of (a), or (c) a coding
sequence which uses the redundancy or degeneracy of the genetic
code to encode the same polypeptides. By "polypeptide" or "protein"
is meant any chain of amino acids, regardless of length or
post-translational modification (e.g., glycosylation or
phosphorylation). Both terms are used interchangeably in the
present application.
[0035] Consistent with the first aspect of the invention, amino
acid sequences are provided which are homologous to SEQ ID No: 2.
As used herein, "homologous amino acid sequence" is any polypeptide
which is encoded, in whole or in part, by a nucleic acid sequence
which hybridizes at 25-35.degree. C. below critical melting
temperature (Tm), to any portion of the nucleic acid sequence of
SEQ ID No: 1. A homologous amino acid sequence is one that differs
from an amino acid sequence shown in SEQ ID No: 2 by one or more
conservative amino acid substitutions. Such a sequence also
encompass serotypic variants (defined below) as well as sequences
containing deletions or insertions which retain inherent
characteristics of the polypeptide such as immunogenicity.
Preferably, such a sequence is at least 75%, more preferably 80%,
and most preferably 90% identical to SEQ ID No: 2.
[0036] Homologous amino acid sequences include sequences that are
identical or substantially identical to SEQ ID No: 2. By "amino
acid sequence substantially identical" is meant a sequence that is
at least 90%, preferably 95%, more preferably 97%, and most
preferably 99% identical to an amino acid sequence of reference and
that preferably differs from the sequence of reference by a
majority of conservative amino acid substitutions.
[0037] Conservative amino acid substitutions are substitutions
among amino acids of the same class. These classes include, for
example, amino acids having uncharged polar side chains, such as
asparagine, glutamine, serine, threonine, and tyrosine; amino acids
having basic side chains, such as lysine, arginine, and histidine;
amino acids having acidic side chains, such as aspartic acid and
glutamic acid; and amino acids having nonpolar side chains, such as
glycine, alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan, and cysteine.
[0038] Homology is measured using sequence analysis software such
as Sequence Analysis Software Package of the Genetics Computer
Group, University of Wisconsin Biotechnology Center, 1710
University Avenue, Madison, Wis. 53705. Amino acid sequences are
aligned to maximize identity. Gaps may be artificially introduced
into the sequence to attain proper alignment. Once the optimal
alignment has been set up, the degree of homology is established by
recording all of the positions in which the amino acids of both
sequences are identical, relative to the total number of
positions.
[0039] Homologous polynucleotide sequences are defined in a similar
way. Preferably, a homologous sequence is one that is at least 45%,
more preferably 60%, even more preferably 75%, even more preferably
85% and most preferably 90% identical to the coding sequence of SEQ
ID No: 1.
[0040] Consistent with the first aspect of the invention,
polypeptides having a sequence homologous to SEQ ID No: 2 include
naturally-occurring allelic variants, as well as mutants or any
other non-naturally occurring variants that retain the inherent
characteristics of the polypeptide of SEQ ID No: 2.
[0041] As is known in the art, an allelic variant is an alternate
form of a polypeptide that is characterized as having a
substitution, deletion, or addition of one or more amino acids that
does not alter the biological function of the polypeptide. By
"biological function" is meant the function of the polypeptide in
the cells in which it naturally occurs, even if the function is not
necessary for the growth or survival of the cells. For example, the
biological function of a porin is to allow the entry into cells of
compounds present in the extracellular medium. Biological function
is distinct from antigenic property. A polypeptide can have more
than one biological function.
[0042] Allelic variants are very common in nature. For example, a
bacterial species such as C. pneumoniae, is usually represented by
a variety of strains that differ from each other by minor allelic
variations. Indeed, a polypeptide that fulfills the same biological
function in different strains can have an amino acid sequence (and
polynucleotide sequence) that is not identical in each of the
strains. Despite this variation, an immune response directed
generally against many allelic variants has been demonstrated. In
studies of the Chlamydial MOMP antigen, cross-strain antibody
binding plus neutralization of infectivity occurs despite amino
acid sequence variation of MOMP from strain to strain, indicating
that the MOMP, when used as an immunogen, is tolerant of amino acid
variations.
[0043] Polynucleotides encoding homologous polypeptides or allelic
variants are retrieved by polymerase chain reaction (PCR)
amplification of genomic bacterial DNA extracted by conventional
methods. This involves the use of synthetic oligonucleotide primers
matching upstream and downstream of the 5' and 3' ends of the
encoding domain. Suitable primers are designed according to the
nucleotide sequence information provided in SEQ ID No:1. The
procedure is as follows: a primer is selected which consists of 10
to 40, preferably 15 to 25 nucleotides. It is advantageous to
select primers containing C and G nucleotides in a proportion
sufficient to ensure efficient hybridization; i.e., an amount of C
and G nucleotides of at least 40%, preferably 50% of the total
nucleotide content. A standard PCR reaction contains typically 0.5
to 5 Units of Taq DNA polymerase per 100 .mu.L, 20 to 200 .mu.M
deoxynucleotide each, preferably at equivalent concentrations, 0.5
to 2.5 mM magnesium over the total deoxynucleotide concentration,
10.sup.5 to 10.sup.6 target molecules, and about 20 .mu.mol of each
primer. About 25 to 50 PCR cycles are performed, with an annealing
temperature 15.degree. C. to 5.degree. C. below the true Tm of the
primers. A more stringent annealing temperature improves
discrimination against incorrectly annealed primers and reduces
incorporation of incorrect nucleotides at the 3' end of primers. A
denaturation temperature of 95.degree. C. to 97.degree. C. is
typical, although higher temperatures may be appropriate for
denaturation of G+C-rich targets. The number of cycles performed
depends on the starting concentration of target molecules, though
typically more than 40 cycles is not recommended as non-specific
background products tend to accumulate.
[0044] An alternative method for retrieving polynucleotides
encoding homologous polypeptides or allelic variants is by
hybridization screening of a DNA or RNA library. Hybridization
procedures are well-known in the art and are described in Ausubel
et al., (Ausubel et al., Current Protocols in Molecular Biology,
John Wiley & Sons Inc., 1994), Silhavy et al. (Silhavy et al.
Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press,
1984), and Davis et al. (Davis et al. A Manual for Genetic
Engineering: Advanced Bacterial Genetics, Cold Spring Harbor
Laboratory Press, 1980)). Important parameters for optimizing
hybridization conditions are reflected in a formula used to obtain
the critical melting temperature above which two complementary DNA
strands separate from each other (Casey & Davidson, Nucl. Acid
Res. (1977) 4:1539). For polynucleotides of about 600 nucleotides
or larger, this formula is as follows: Tm=81.5+0.41.times.(%
G+C)+16.6 log (cation ion concentration)-0.63.times.(%
formamide)-600/base number. Under appropriate stringency
conditions, hybridization temperature (Th) is approximately 20 to
40.degree. C., 20 to 25.degree. C., or, preferably 30 to 40.degree.
C. below the calculated Tm. Those skilled in the art will
understand that optimal temperature and salt conditions can be
readily determined.
[0045] For the polynucleotides of the invention, stringent
conditions are achieved for both pre-hybridizing and hybridizing
incubations (i) within 4-16 hours at 42.degree. C., in 6.times.SSC
containing 50% formamide, or (ii) within 4-16 hours at 65.degree.
C. in an aqueous 6.times.SSC solution (1 M NaCl, 0.1 M sodium
citrate (pH 7.0)). Typically, hybridization experiments are
performed at a temperature from 60 to 68.degree. C., e.g.
65.degree. C. At such a temperature, stringent hybridization
conditions can be achieved in 6.times.SSC, preferably in
2.times.SSC or 1.times.SSC, more preferably in 0.5.times.SSc,
0.3.times.SSC or 0.1.times.SSC (in the absence of formamide).
1.times.SSC contains 0.15 M NaCl and 0.015 M sodium citrate.
[0046] Useful homologs and fragments thereof that do not occur
naturally are designed using known methods for identifying regions
of an antigen that are likely to tolerate amino acid sequence
changes and/or deletions. As an example, homologous polypeptides
from different species are compared; conserved sequences are
identified. The more divergent sequences are the most likely to
tolerate sequence changes. Homology among sequences may be analyzed
using, as an example, the BLAST homology searching algorithm of
Altschul et al., Nucleic Acids Res.; 25:3389-3402 (1997).
Alternatively, sequences are modified such that they become more
reactive to T- and/or B-cells, based on computer-assisted analysis
of probable T- or B-cell epitopes Yet another alternative is to
mutate a particular amino acid residue or sequence within the
polypeptide in vitro, then screen the mutant polypeptides for their
ability to prevent or treat Chlamydia infection according to the
method outlined below.
[0047] A person skilled in the art will readily understand that by
following the screening process of this invention, it will be
determined without undue experimentation whether a particular
homolog of SEQ ID No. 2 may be useful in the prevention or
treatment of Chlamydia infection. The screening procedure comprises
the steps:
(i) immunizing an animal, preferably mouse, with the test homolog
or fragment; (ii) inoculating the immunized animal with Chlamydia;
and (iii) selecting those homologs or fragments which confer
protection against Chlamydia.
[0048] By "conferring protection" is meant that there is a
reduction in severity of any of the effects of Chlamydia infection,
in comparison with a control animal which was not immunized with
the test homolog or fragment.
[0049] Consistent with the first aspect of the invention,
polypeptide derivatives are provided that are partial sequences of
SEQ ID No. 2, partial sequences of polypeptide sequences homologous
to SEQ ID No. 2, polypeptides derived from full-length polypeptides
by internal deletion, and fusion proteins.
[0050] It is an accepted practice in the field of immunology to use
fragments and variants of protein immunogens as vaccines, as all
that is required to induce an immune response to a protein is a
small (e.g., 8 to 10 amino acid) immunogenic region of the protein.
Various short synthetic peptides corresponding to surface-exposed
antigens of pathogens other than Chlamydia have been shown to be
effective vaccine antigens against their respective pathogens, e.g.
an 11 residue peptide of murine mammary tumor virus (Casey &
Davidson, Nucl. Acid Res. (1977) 4:1539), a 16-residue peptide of
Semliki Forest virus (Snijders et al., 1991. J. Gen. Virol.
72:557-565), and two overlapping peptides of 15 residues each from
canine parvovirus (Langeveld et al., Vaccine 12(15):1473-1480,
1994).
[0051] Accordingly, it will be readily apparent to one skilled in
the art, having read the present description, that partial
sequences of SEQ ID No: 2 or their homologous amino acid sequences
are inherent to the full-length sequences and are taught by the
present invention. Such polypeptide fragments preferably are at
least 12 amino acids in length. Advantageously, they are at least
20 amino acids, preferably at least 50 amino acids, more preferably
at least 75 amino acids, and most preferably at least 100 amino
acids in length.
[0052] Polynucleotides of 30 to 600 nucleotides encoding partial
sequences of sequences homologous to SEQ ID No: 2 are retrieved by
PCR amplification using the parameters outlined above and using
primers matching the sequences upstream and downstream of the 5'
and 3' ends of the fragment to be amplified. The template
polynucleotide for such amplification is either the full length
polynucleotide homologous to SEQ ID No: 1, or a polynucleotide
contained in a mixture of polynucleotides such as a DNA or RNA
library. As an alternative method for retrieving the partial
sequences, screening hybridization is carried out under conditions
described above and using the formula for calculating Tm. Where
fragments of 30 to 600 nucleotides are to be retrieved, the
calculated Tm is corrected by subtracting (600/polynucleotide size
in base pairs) and the stringency conditions are defined by a
hybridization temperature that is 5 to 10.degree. C. below Tm.
Where oligonucleotides shorter than 20-30 bases are to be obtained,
the formula for calculating the Tm is as follows:
Tm=4.times.(G+C)+2 (A+T). For example, an 18 nucleotide fragment of
50% G+C would have an approximate Tm of 54.degree. C. Short
peptides that are fragments of SEQ ID No: 2 or its homologous
sequences, are obtained directly by chemical synthesis (E. Gross
and H. J. Meinhofer, 4 The Peptides: Analysis, Synthesis, Biology;
Modern Techniques of Peptide Synthesis, John Wiley & Sons
(1981), and M. Bodanzki, Principles of Peptide Synthesis,
Springer-Verlag (1984)).
[0053] Useful polypeptide derivatives, e.g., polypeptide fragments,
are designed using computer-assisted analysis of amino acid
sequences. This would identify probable surface-exposed, antigenic
regions (Hughes et al., 1992. Infect. Immun. 60(9):3497). Analysis
of 6 amino acid sequences contained in SEQ ID No: 2, based on the
product of flexibility and hydrophobicity propensities using the
program SEQSEE (Wishart D S, et al. "SEQSEE: a comprehensive
program suite for protein sequence analysis." Comput Appl Biosci.
1994 April; 10(2):121-32), can reveal potential B- and T-cell
epitopes which may be used as a basis for selecting useful
immunogenic fragments and variants. This analysis uses a reasonable
combination of external surface features that is likely to be
recognized by antibodies. Probable T-cell epitopes for HLA-A0201
MHC subclass may be revealed by an algorithms that emulate an
approach developed at the NIH (Parker K C, et al. "Peptide binding
to MHC class I molecules: implications for antigenic peptide
prediction." Immunol Res 1995; 14(1):34-57).
[0054] Epitopes which induce a protective T cell-dependent immune
response are present throughout the length of the polypeptide.
However, some epitopes may be masked by secondary and tertiary
structures of the polypeptide. To reveal such masked epitopes large
internal deletions are created which remove much of the original
protein structure and exposes the masked epitopes. Such internal
deletions sometimes effect the additional advantage of removing
immunodominant regions of high variability among strains.
[0055] Polynucleotides encoding polypeptide fragments and
polypeptides having large internal deletions are constructed using
standard methods (Ausubel et al., Current Protocols in Molecular
Biology, John Wiley & Sons Inc., 1994). Such methods include
standard PCR, inverse PCR, restriction enzyme treatment of cloned
DNA molecules, or the method of Kunkel et al. (Kunkel et al. Proc.
Natl. Acad. Sci. USA (1985) 82:448). Components for these methods
and instructions for their use are readily available from various
commercial sources such as Stratagene. Once the deletion mutants
have been constructed, they are tested for their ability to prevent
or treat Chlamydia infection as described above.
[0056] As used herein, a fusion polypeptide is one that contains a
polypeptide or a polypeptide derivative of the invention fused at
the N- or C-terminal end to any other polypeptide (hereinafter
referred to as a peptide tail). A simple way to obtain such a
fusion polypeptide is by translation of an in-frame fusion of the
polynucleotide sequences, i.e., a hybrid gene. The hybrid gene
encoding the fusion polypeptide is inserted into an expression
vector which is used to transform or transfect a host cell.
Alternatively, the polynucleotide sequence encoding the polypeptide
or polypeptide derivative is inserted into an expression vector in
which the polynucleotide encoding the peptide tail is already
present. Such vectors and instructions for their use are
commercially available, e.g. the pMal-c2 or pMal-p2 system from New
England Biolabs, in which the peptide tail is a maltose binding
protein, the glutathione-5-transferase system of Pharmacia, or the
His-Tag system available from Novagen. These and other expression
systems provide convenient means for further purification of
polypeptides and derivatives of the invention.
[0057] An advantageous example of a fusion polypeptide is one where
the polypeptide or homolog or fragment of the invention is fused to
a polypeptide having adjuvant activity, such as subunit B of either
cholera toxin or E. coli heat-labile toxin. Another advantageous
fusion is one where the polypeptide, homolog or fragment is fused
to a strong T-cell epitope or B-cell epitope. Such an epitope may
be one known in the art (e.g. the Hepatitis B virus core antigen,
D. R. Millich et al., "Antibody production to the nucleocapsid and
envelope of the Hepatitis B virus primed by a single synthetic T
cell site", Nature. 1987. 329:547-549), or one which has been
identified in another polypeptide of the invention based on
computer-assisted analysis of probable T- or B-cell epitopes.
Consistent with this aspect of the invention is a fusion
polypeptide comprising T- or B-cell epitopes from SEQ ID No: 2 or
its homolog or fragment, wherein the epitopes are derived from
multiple variants of said polypeptide or homolog or fragment, each
variant differing from another in the location and sequence of its
epitope within the polypeptide. Such a fusion is effective in the
prevention and treatment of Chlamydia infection since it optimizes
the T- and B-cell response to the overall polypeptide, homolog or
fragment.
[0058] To effect fusion, the polypeptide of the invention is fused
to the N-, or preferably, to the C-terminal end of the polypeptide
having adjuvant activity or T- or B-cell epitope. Alternatively, a
polypeptide fragment of the invention is inserted internally within
the amino acid sequence of the polypeptide having adjuvant
activity. The T- or B-cell epitope may also be inserted internally
within the amino acid sequence of the polypeptide of the
invention.
[0059] Consistent with the first aspect, the polynucleotides of the
invention also encode hybrid precursor polypeptides containing
heterologous signal peptides, which mature into polypeptides of the
invention. By "heterologous signal peptide" is meant a signal
peptide that is not found in naturally-occurring precursors of
polypeptides of the invention.
[0060] Polynucleotide molecules according to the invention,
including RNA, DNA, or modifications or combinations thereof, have
various applications. A DNA molecule is used, for example, (i) in a
process for producing the encoded polypeptide in a recombinant host
system, (ii) in the construction of vaccine vectors such as
poxviruses, which are further used in methods and compositions for
preventing and/or treating Chlamydia infection, (iii) as a vaccine
agent (as well as an RNA molecule), in a naked form or formulated
with a delivery vehicle and, (iv) in the construction of attenuated
Chlamydia strains that can over-express a polynucleotide of the
invention or express it in a non-toxic, mutated form.
[0061] Accordingly, a second aspect of the invention encompasses
(i) an expression cassette containing a DNA molecule of the
invention placed under the control of the elements required for
expression, in particular under the control of an appropriate
promoter; (ii) an expression vector containing an expression
cassette of the invention; (iii) a procaryotic or eucaryotic cell
transformed or transfected with an expression cassette and/or
vector of the invention, as well as (iv) a process for producing a
polypeptide or polypeptide derivative encoded by a polynucleotide
of the invention, which involves culturing a procaryotic or
eucaryotic cell transformed or transfected with an expression
cassette and/or vector of the invention, under conditions that
allow expression of the DNA molecule of the invention and,
recovering the encoded polypeptide or polypeptide derivative from
the cell culture.
[0062] A recombinant expression system is selected from procaryotic
and eucaryotic hosts. Eucaryotic hosts include yeast cells (e.g.,
Saccharomyces cerevisiae or Pichia pastoris), mammalian cells
(e.g., COS1, NIH3T3, or JEG3 cells), arthropods cells (e.g.,
Spodoptera frugiperda (SF9) cells), and plant cells. A preferred
expression system is a procaryotic host such as E. coli. Bacterial
and eucaryotic cells are available from a number of different
sources including commercial sources to those skilled in the art,
e.g., the American Type Culture Collection (ATCC; 10801 University
Boulevard, Manassas, Va. 20110-2209). Commercial sources of cells
used for recombinant protein expression also provide instructions
for usage of the cells.
[0063] The choice of the expression system depends on the features
desired for the expressed polypeptide. For example, it may be
useful to produce a polypeptide of the invention in a particular
lipidated form or any other form.
[0064] One skilled in the art would readily understand that not all
vectors and expression control sequences and hosts would be
expected to express equally well the polynucleotides of this
invention. With the guidelines described below, however, a
selection of vectors, expression control sequences and hosts may be
made without undue experimentation and without departing from the
scope of this invention.
[0065] In selecting a vector, the host must be chosen that is
compatible with the vector which is to exist and possibly replicate
in it. Considerations are made with respect to the vector copy
number, the ability to control the copy number, expression of other
proteins such as antibiotic resistance. In selecting an expression
control sequence, a number of variables are considered. Among the
important variable are the relative strength of the sequence (e.g.
the ability to drive expression under various conditions), the
ability to control the sequence's function, compatibility between
the polynucleotide to be expressed and the control sequence (e.g.
secondary structures are considered to avoid hairpin structures
which prevent efficient transcription). In selecting the host,
unicellular hosts are selected which are compatible with the
selected vector, tolerant of any possible toxic effects of the
expressed product, able to secrete the expressed product
efficiently if such is desired, to be able to express the product
in the desired conformation, to be easily scaled up, and to which
ease of purification of the final product.
[0066] The choice of the expression cassette depends on the host
system selected as well as the features desired for the expressed
polypeptide. Typically, an expression cassette includes a promoter
that is functional in the selected host system and can be
constitutive or inducible; a ribosome binding site; a start codon
(ATG) if necessary; a region encoding a signal peptide, e.g., a
lipidation signal peptide; a DNA molecule of the invention; a stop
codon; and optionally a 3' terminal region (translation and/or
transcription terminator). The signal peptide encoding region is
adjacent to the polynucleotide of the invention and placed in
proper reading frame. The signal peptide-encoding region is
homologous or heterologous to the DNA molecule encoding the mature
polypeptide and is compatible with the secretion apparatus of the
host used for expression. The open reading frame constituted by the
DNA molecule of the invention, solely or together with the signal
peptide, is placed under the control of the promoter so that
transcription and translation occur in the host system. Promoters
and signal peptide encoding regions are widely known and available
to those skilled in the art and include, for example, the promoter
of Salmonella typhimurium (and derivatives) that is inducible by
arabinose (promoter araB) and is functional in Gram-negative
bacteria such as E. coli (as described in U.S. Pat. No. 5,028,530
and in Cagnon et al., (Cagnon et al., Protein Engineering (1991)
4(7):843)); the promoter of the gene of bacteriophage T7 encoding
RNA polymerase, that is functional in a number of E. coli strains
expressing T7 polymerase (described in U.S. Pat. No. 4,952,496);
OspA lipidation signal peptide; and RlpB lipidation signal peptide
(Takase et al., J. Bact. (1987) 169:5692).
[0067] The expression cassette is typically part of an expression
vector, which is selected for its ability to replicate in the
chosen expression system. Expression vectors (e.g., plasmids or
viral vectors) can be chosen, for example, from those described in
Pouwels et al. (Cloning Vectors: A Laboratory Manual 1985, Supp.
1987). Suitable expression vectors can be purchased from various
commercial sources.
[0068] Methods for transforming/transfecting host cells with
expression vectors are well-known in the art and depend on the host
system selected as described in Ausubel et al., (Ausubel et al.,
Current Protocols in Molecular Biology, John Wiley & Sons Inc.,
1994).
[0069] Upon expression, a recombinant polypeptide of the invention
(or a polypeptide derivative) is produced and remains in the
intracellular compartment, is secreted/excreted in the
extracellular medium or in the periplasmic space, or is embedded in
the cellular membrane. The polypeptide is recovered in a
substantially purified form from the cell extract or from the
supernatant after centrifugation of the recombinant cell culture.
Typically, the recombinant polypeptide is purified by
antibody-based affinity purification or by other well-known methods
that can be readily adapted by a person skilled in the art, such as
fusion of the polynucleotide encoding the polypeptide or its
derivative to a small affinity binding domain. Antibodies useful
for purifying by immunoaffinity the polypeptides of the invention
are obtained as described below.
[0070] A polynucleotide of the invention can also be useful as a
vaccine. There are two major routes, either using a viral or
bacterial host as gene delivery vehicle (live vaccine vector) or
administering the gene in a free form, e.g., inserted into a
plasmid. Therapeutic or prophylactic efficacy of a polynucleotide
of the invention is evaluated as described below.
[0071] Accordingly, a third aspect of the invention provides (i) a
vaccine vector such as a poxvirus, containing a DNA molecule of the
invention, placed under the control of elements required for
expression; (ii) a composition of matter comprising a vaccine
vector of the invention, together with a diluent or carrier;
specifically (iii) a pharmaceutical composition containing a
therapeutically or prophylactically effective amount of a vaccine
vector of the invention; (iv) a method for inducing an immune
response against Chlamydia in a mammal (e.g., a human;
alternatively, the method can be used in veterinary applications
for treating or preventing Chlamydia infection of animals, e.g.,
cats or birds), which involves administering to the mammal an
immunogenically effective amount of a vaccine vector of the
invention to elicit a protective or therapeutic immune response to
Chlamydia; and particularly, (v) a method for preventing and/or
treating a Chlamydia (e.g., C. trachomatis, C. psittaci, C.
pneumonia, C. pecorum) infection, which involves administering a
prophylactic or therapeutic amount of a vaccine vector of the
invention to an infected individual. Additionally, the third aspect
of the invention encompasses the use of a vaccine vector of the
invention in the preparation of a medicament for preventing and/or
treating Chlamydia infection.
[0072] As used herein, a vaccine vector expresses one or several
polypeptides or derivatives of the invention. The vaccine vector
may express additionally a cytokine, such as interleukin-2 (IL-2)
or interleukin-12 (IL-12), that enhances the immune response
(adjuvant effect). It is understood that each of the components to
be expressed is placed under the control of elements required for
expression in a mammalian cell.
[0073] Consistent with the third aspect of the invention is a
composition comprising several vaccine vectors, each of them
capable of expressing a polypeptide or derivative of the invention.
A composition may also comprise a vaccine vector capable of
expressing an additional Chlamydia antigen, or a subunit, fragment,
homolog, mutant, or derivative thereof; optionally together with or
a cytokine such as IL-2 or IL-12.
[0074] Vaccination methods for treating or preventing infection in
a mammal comprises use of a vaccine vector of the invention to be
administered by any conventional route, particularly to a mucosal
(e.g., ocular, intranasal, oral, gastric, pulmonary, intestinal,
rectal, vaginal, or urinary tract) surface or via the parenteral
(e.g., subcutaneous, intradermal, intramuscular, intravenous, or
intraperitoneal) route. Preferred routes depend upon the choice of
the vaccine vector. Treatment may be effected in a single dose or
repeated at intervals. The appropriate dosage depends on various
parameters understood by skilled artisans such as the vaccine
vector itself, the route of administration or the condition of the
mammal to be vaccinated (weight, age and the like).
[0075] Live vaccine vectors available in the art include viral
vectors such as adenoviruses and poxviruses as well as bacterial
vectors, e.g., Shigella, Salmonella, Vibrio cholerae,
Lactobacillus, Bacille bilie de Calmette-Guerin (BCG), and
Streptococcus.
[0076] An example of an adenovirus vector, as well as a method for
constructing an adenovirus vector capable of expressing a DNA
molecule of the invention, are described in U.S. Pat. No.
4,920,209. Poxvirus vectors include vaccinia and canary pox virus,
described in U.S. Pat. No. 4,722,848 and U.S. Pat. No. 5,364,773,
respectively. (Also see, e.g., Tartaglia et al., Virology (1992)
188:217) for a description of a vaccinia virus vector and Taylor et
al, Vaccine (1995) 13:539 for a reference of a canary pox.)
Poxvirus vectors capable of expressing a polynucleotide of the
invention are obtained by homologous recombination as described in
Kieny et al., Nature (1984) 312:163 so that the polynucleotide of
the invention is inserted in the viral genome under appropriate
conditions for expression in mammalian cells. Generally, the dose
of vaccine viral vector, for therapeutic or prophylactic use, can
be of from about 1.times.10.sup.4 to about 1.times.10.sup.11,
advantageously from about 1.times.10.sup.7 to about
1.times.10.sup.10, preferably of from about 1.times.10.sup.7 to
about 1.times.10.sup.9 plaque-forming units per kilogram.
Preferably, viral vectors are administered parenterally; for
example, in 3 doses, 4 weeks apart. It is preferable to avoid
adding a chemical adjuvant to a composition containing a viral
vector of the invention and thereby minimizing the immune response
to the viral vector itself.
[0077] Non-toxicogenic Vibrio cholerae mutant strains that are
useful as a live oral vaccine are known. Mekalanos et al., Nature
(1983) 306:551 and U.S. Pat. No. 4,882,278 describe strains which
have a substantial amount of the coding sequence of each of the two
ctxA alleles deleted so that no functional cholerae toxin is
produced. WO 92/11354 describes a strain in which the irgA locus is
inactivated by mutation; this mutation can be combined in a single
strain with ctxA mutations. WO 94/01533 describes a deletion mutant
lacking functional ctxA and attRS1 DNA sequences. These mutant
strains are genetically engineered to express heterologous
antigens, as described in WO 94/19482. An effective vaccine dose of
a Vibrio cholerae strain capable of expressing a polypeptide or
polypeptide derivative encoded by a DNA molecule of the invention
contains about 1.times.10.sup.5 to about 1.times.10.sup.9,
preferably about 1.times.10.sup.6 to about 1.times.10.sup.8, viable
bacteria in a volume appropriate for the selected route of
administration. Preferred routes of administration include all
mucosal routes; most preferably, these vectors are administered
intranasally or orally.
[0078] Attenuated Salmonella typhimurium strains, genetically
engineered for recombinant expression of heterologous antigens or
not, and their use as oral vaccines are described in Nakayama et
al. (Bio/Technology (1988) 6:693) and WO 92/11361. Preferred routes
of administration include all mucosal routes; most preferably,
these vectors are administered intranasally or orally.
[0079] Other bacterial strains used as vaccine vectors in the
context of the present invention are described for Shigella
flexneri in High et al., EMBO (1992) 11:1991 and Sizemore et al.,
Science (1995) 270:299; for Streptococcus gordonii in Medaglini et
al., Proc. Natl. Acad. Sci. USA (1995) 92:6868; and for Bacille
Calmette Guerin in Flynn J. L., Cell. Mol. Biol. (1994) 40 (suppl.
I):31, WO 88/06626, WO 90/00594, WO 91/13157, WO 92/01796, and WO
92/21376.
[0080] In bacterial vectors, the polynucleotide of the invention is
inserted into the bacterial genome or remains in a free state as
part of a plasmid.
[0081] The composition comprising a vaccine bacterial vector of the
present invention may further contain an adjuvant. A number of
adjuvants are known to those skilled in the art. Preferred
adjuvants are selected as provided below.
[0082] Accordingly, a fourth aspect of the invention provides (i) a
composition of matter comprising a polynucleotide of the invention,
together with a diluent or carrier; (ii) a pharmaceutical
composition comprising a therapeutically or prophylactically
effective amount of a polynucleotide of the invention; (iii) a
method for inducing an immune response against Chlamydia in a
mammal by administration of an immunogenically effective amount of
a polynucleotide of the invention to elicit a protective immune
response to Chlamydia; and particularly, (iv) a method for
preventing and/or treating a Chlamydia (e.g., C. trachomatis, C.
psittaci, C. pneumoniae, or C. pecorum) infection, by administering
a prophylactic or therapeutic amount of a polynucleotide of the
invention to an infected individual. Additionally, the fourth
aspect of the invention encompasses the use of a polynucleotide of
the invention in the preparation of a medicament for preventing
and/or treating Chlamydia infection. A preferred use includes the
use of a DNA molecule placed under conditions for expression in a
mammalian cell, especially in a plasmid that is unable to replicate
in mammalian cells and to substantially integrate in a mammalian
genome.
[0083] Use of the polynucleotides of the invention include their
administration to a mammal as a vaccine, for therapeutic or
prophylactic purposes. Such polynucleotides are used in the form of
DNA as part of a plasmid that is unable to replicate in a mammalian
cell and unable to integrate into the mammalian genome. Typically,
such a DNA molecule is placed under the control of a promoter
suitable for expression in a mammalian cell. The promoter functions
either ubiquitously or tissue-specifically. Examples of non-tissue
specific promoters include the early Cytomegalovirus (CMV) promoter
(described in U.S. Pat. No. 4,168,062) and the Rous Sarcoma Virus
promoter (described in Norton & Coffin, Molec. Cell Biol.
(1985) 5:281). An example of a tissue-specific promoter is the
desmin promoter which drives expression in muscle cells (Li et al.,
Gene (1989) 78:243, Li & Paulin, J. Biol. Chem. (1991) 266:6562
and Li & Paulin, J. Biol. Chem. (1993) 268:10403). Use of
promoters is well-known to those skilled in the art. Useful vectors
are described in numerous publications, specifically WO 94/21797
and Hartikka et al., Human Gene Therapy (1996) 7:1205.
[0084] Polynucleotides of the invention which are used as vaccines
encode either a precursor or a mature form of the corresponding
polypeptide. In the precursor form, the signal peptide is either
homologous or heterologous. In the latter case, a eucaryotic leader
sequence such as the leader sequence of the tissue-type plasminogen
factor (tPA) is preferred.
[0085] As used herein, a composition of the invention contains one
or several polynucleotides with optionally at least one additional
polynucleotide encoding another Chlamydia antigen such as urease
subunit A, B, or both, or a fragment, derivative, mutant, or analog
thereof. The composition may also contain an additional
polynucleotide encoding a cytokine, such as interleukin-2 (IL-2) or
interleukin-12 (IL-12) so that the immune response is enhanced.
These additional polynucleotides are placed under appropriate
control for expression. Advantageously, DNA molecules of the
invention and/or additional DNA molecules to be included in the
same composition, are present in the same plasmid.
[0086] Standard techniques of molecular biology for preparing and
purifying polynucleotides are used in the preparation of
polynucleotide therapeutics of the invention. For use as a vaccine,
a polynucleotide of the invention is formulated according to
various methods outlined below.
[0087] One method utilizes the polynucleotide in a naked form, free
of any delivery vehicles. Such a polynucleotide is simply diluted
in a physiologically acceptable solution such as sterile saline or
sterile buffered saline, with or without a carrier. When present,
the carrier preferably is isotonic, hypotonic, or weakly
hypertonic, and has a relatively low ionic strength, such as
provided by a sucrose solution, e.g., a solution containing 20%
sucrose.
[0088] An alternative method utilizes the polynucleotide in
association with agents that assist in cellular uptake. Examples of
such agents are (i) chemicals that modify cellular permeability,
such as bupivacaine (see, e.g., WO 94/16737), (ii) liposomes for
encapsulation of the polynucleotide, or (iii) cationic lipids or
silica, gold, or tungsten microparticles which associate themselves
with the polynucleotides.
[0089] Anionic and neutral liposomes are well-known in the art
(see, e.g., Liposomes: A Practical Approach, RPC New Ed, IRL press
(1990), for a detailed description of methods for making liposomes)
and are useful for delivering a large range of products, including
polynucleotides.
[0090] Cationic lipids are also known in the art and are commonly
used for gene delivery. Such lipids include Lipofectin.TM. also
known as DOTMA
(N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride),
DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB
(dimethyldioctadecylammonium bromide), DOGS
(dioctadecylamidologlycyl spermine) and cholesterol derivatives
such as DC-Chol (3 beta-(N--(N',N'-dimethyl
aminomethane)-carbamoyl) cholesterol). A description of these
cationic lipids can be found in EP 187,702, WO 90/11092, U.S. Pat.
No. 5,283,185, WO 91/15501, WO 95/26356, and U.S. Pat. No.
5,527,928. Cationic lipids for gene delivery are preferably used in
association with a neutral lipid such as DOPE (dioleyl
phosphatidylethanolamine), as described in WO 90/11092 as an
example.
[0091] Formulation containing cationic liposomes may optionally
contain other transfection-facilitating compounds. A number of them
are described in WO 93/18759, WO 93/19768, WO 94/25608, and WO
95/02397. They include spermine derivatives useful for facilitating
the transport of DNA through the nuclear membrane (see, for
example, WO 93/18759) and membrane-permeabilizing compounds such as
GAL4, Gramicidine S, and cationic bile salts (see, for example, WO
93/19768).
[0092] Gold or tungsten microparticles are used for gene delivery,
as described in WO 91/00359, WO 93/17706, and Tang et al. Nature
(1992) 356:152. The microparticle-coated polynucleotide is injected
via intradermal or intraepidermal routes using a needleless
injection device ("gene gun"), such as those described in U.S. Pat.
No. 4,945,050, U.S. Pat. No. 5,015,580, and WO 94/24263.
[0093] The amount of DNA to be used in a vaccine recipient depends,
e.g., on the strength of the promoter used in the DNA construct,
the immunogenicity of the expressed gene product, the condition of
the mammal intended for administration (e.g., the weight, age, and
general health of the mammal), the mode of administration, and the
type of formulation. In general, a therapeutically or
prophylactically effective dose from about 1 .mu.g to about 1 mg,
preferably, from about 10 .mu.g to about 800 .mu.g and, more
preferably, from about 25 .mu.g to about 250 .mu.g, can be
administered to human adults. The administration can be achieved in
a single dose or repeated at intervals.
[0094] The route of administration is any conventional route used
in the vaccine field. As general guidance, a polynucleotide of the
invention is administered via a mucosal surface, e.g., an ocular,
intranasal, pulmonary, oral, intestinal, rectal, vaginal, and
urinary tract surface; or via a parenteral route, e.g., by an
intravenous, subcutaneous, intraperitoneal, intradermal,
intraepidermal, or intramuscular route. The choice of
administration route depends on the formulation that is selected. A
polynucleotide formulated in association with bupivacaine is
advantageously administered into muscles. When a neutral or anionic
liposome or a cationic lipid, such as DOTMA or DC-Chol, is used,
the formulation can be advantageously injected via intravenous,
intranasal (aerosolization), intramuscular, intradermal, and
subcutaneous routes. A polynucleotide in a naked form can
advantageously be administered via the intramuscular, intradermal,
or sub-cutaneous routes.
[0095] Although not absolutely required, such a composition can
also contain an adjuvant. If so, a systemic adjuvant that does not
require concomitant administration in order to exhibit an adjuvant
effect is preferable such as, e.g., QS21, which is described in
U.S. Pat. No. 5,057,546.
[0096] The sequence information provided in the present application
enables the design of specific nucleotide probes and primers that
are used for diagnostic purposes.
[0097] Accordingly, a fifth aspect of the invention provides a
nucleotide probe or primer having a sequence found in or derived by
degeneracy of the genetic code from a sequence shown in SEQ ID
No:1.
[0098] The term "probe" as used in the present application refers
to DNA (preferably single stranded) or RNA molecules (or
modifications or combinations thereof) that hybridize under the
stringent conditions, as defined above, to nucleic acid molecules
having SEQ ID No:1 or to sequences homologous to SEQ ID No:1, or to
its complementary or anti-sense sequence. Generally, probes are
significantly shorter than full-length sequences. Such probes
contain from about 5 to about 100, preferably from about 10 to
about 80, nucleotides. In particular, probes have sequences that
are at least 75%, preferably at least 85%, more preferably 95%
homologous to a portion of SEQ ID No:1 or that are complementary to
such sequences. Probes may contain modified bases such as inosine,
methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine,
or diamino-2,6-purine. Sugar or phosphate residues may also be
modified or substituted. For example, a deoxyribose residue may be
replaced by a polyamide (Nielsen et al., Science (1991) 254:1497)
and phosphate residues may be replaced by ester groups such as
diphosphate, alkyl, arylphosphonate and phosphorothioate esters. In
addition, the 2'-hydroxyl group on ribonucleotides may be modified
by including such groups as alkyl groups.
[0099] Probes of the invention are used in diagnostic tests, as
capture or detection probes. Such capture probes are conventionally
immobilized on a solid support, directly or indirectly, by covalent
means or by passive adsorption. A detection probe is labelled by a
detection marker selected from: radioactive isotopes, enzymes such
as peroxidase, alkaline phosphatase, and enzymes able to hydrolyze
a chromogenic, fluorogenic, or luminescent substrate, compounds
that are chromogenic, fluorogenic, or luminescent, nucleotide base
analogs, and biotin.
[0100] Probes of the invention are used in any conventional
hybridization technique, such as dot blot (Maniatis et al.,
Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.), Southern blot
(Southern, J. Mol. Biol. (1975) 98:503), northern blot (identical
to Southern blot with the exception that RNA is used as a target),
or the sandwich technique (Dunn et al., Cell (1977) 12:23). The
latter technique involves the use of a specific capture probe
and/or a specific detection probe with nucleotide sequences that at
least partially differ from each other.
[0101] A primer is a probe of usually about 10 to about 40
nucleotides that is used to initiate enzymatic polymerization of
DNA in an amplification process (e.g., PCR), in an elongation
process, or in a reverse transcription method. Primers used in
diagnostic methods involving PCR are labeled by methods known in
the art.
[0102] As described herein, the invention also encompasses (i) a
reagent comprising a probe of the invention for detecting and/or
identifying the presence of Chlamydia in a biological material;
(ii) a method for detecting and/or identifying the presence of
Chlamydia in a biological material, in which (a) a sample is
recovered or derived from the biological material, (b) DNA or RNA
is extracted from the material and denatured, and (c) exposed to a
probe of the invention, for example, a capture, detection probe or
both, under stringent hybridization conditions, such that
hybridization is detected; and (iii) a method for detecting and/or
identifying the presence of Chlamydia in a biological material, in
which (a) a sample is recovered or derived from the biological
material, (b) DNA is extracted therefrom, (c) the extracted DNA is
primed with at least one, and preferably two, primers of the
invention and amplified by polymerase chain reaction, and (d) the
amplified DNA fragment is produced.
[0103] It is apparent that disclosure of polynucleotide sequences
of SEQ ID No:1, its homologs and partial sequences enable their
corresponding amino acid sequences. Accordingly, a sixth aspect of
the invention features a substantially purified polypeptide or
polypeptide derivative having an amino acid sequence encoded by a
polynucleotide of the invention.
[0104] A "substantially purified polypeptide" as used herein is
defined as a polypeptide that is separated from the environment in
which it naturally occurs and/or that is free of the majority of
the polypeptides that are present in the environment in which it
was synthesized. For example, a substantially purified polypeptide
is free from cytoplasmic polypeptides. Those skilled in the art
would readily understand that the polypeptides of the invention may
be purified from a natural source, i.e., a Chlamydia strain, or
produced by recombinant means.
[0105] Consistent with the sixth aspect of the invention are
polypeptides, homologs or fragments which are modified or treated
to enhance their immunogenicity in the target animal, in whom the
polypeptide, homolog or fragments are intended to confer protection
against Chlamydia. Such modifications or treatments include: amino
acid substitutions with an amino acid derivative such as
3-methyhistidine, 4-hydroxyproline, 5-hydroxylysine etc.,
modifications or deletions which are carried out after preparation
of the polypeptide, homolog or fragment, such as the modification
of free amino, carboxyl or hydroxyl side groups of the amino
acids.
[0106] Identification of homologous polypeptides or polypeptide
derivatives encoded by polynucleotides of the invention which have
specific antigenicity is achieved by screening for cross-reactivity
with an antiserum raised against the polypeptide of reference
having an amino acid sequence of SEQ ID No:1. The procedure is as
follows: a monospecific hyperimmune antiserum is raised against a
purified reference polypeptide, a fusion polypeptide (for example,
an expression product of MBP, GST, or His-tag systems, the
description and instructions for use of which are contained in
Invitrogen product manuals for pcDNA3.1/Myc-His(+) A, B, and C and
for the Xpress.TM. System Protein Purification), or a synthetic
peptide predicted to be antigenic. Where an antiserum is raised
against a fusion polypeptide, two different fusion systems are
employed. Specific antigenicity can be determined according to a
number of methods, including Western blot (Towbin et al., Proc.
Natl. Acad. Sci. USA (1979) 76:4350), dot blot, and ELISA, as
described below.
[0107] In a Western blot assay, the product to be screened, either
as a purified preparation or a total E. coli extract, is submitted
to SDS-Page electrophoresis as described by Laemmli (Nature (1970)
227:680). After transfer to a nitrocellulose membrane, the material
is further incubated with the monospecific hyperimmune antiserum
diluted in the range of dilutions from about 1:5 to about 1:5000,
preferably from about 1:100 to about 1:500. Specific antigenicity
is shown once a band corresponding to the product exhibits
reactivity at any of the dilutions in the above range.
[0108] In an ELISA assay, the product to be screened is preferably
used as the coating antigen. A purified preparation is preferred,
although a whole cell extract can also be used. Briefly, about 100
.mu.l of a preparation at about 10 .mu.g protein/ml are distributed
into wells of a 96-well polycarbonate ELISA plate. The plate is
incubated for 2 hours at 37.degree. C. then overnight at 4.degree.
C. The plate is washed with phosphate buffer saline (PBS)
containing 0.05% Tween 20 (PBS/Tween buffer). The wells are
saturated with 250 .mu.l PBS containing 1% bovine serum albumin
(BSA) to prevent non-specific antibody binding. After 1 hour
incubation at 37.degree. C., the plate is washed with PBS/Tween
buffer. The antiserum is serially diluted in PBS/Tween buffer
containing 0.5% BSA. 100 .mu.l of dilutions are added per well. The
plate is incubated for 90 minutes at 37.degree. C., washed and
evaluated according to standard procedures. For example, a goat
anti-rabbit peroxidase conjugate is added to the wells when
specific antibodies were raised in rabbits. Incubation is carried
out for 90 minutes at 37.degree. C. and the plate is washed. The
reaction is developed with the appropriate substrate and the
reaction is measured by colorimetry (absorbance measured
spectrophotometrically). Under the above experimental conditions, a
positive reaction is shown by O.D. values greater than a non immune
control serum.
[0109] In a dot blot assay, a purified product is preferred,
although a whole cell extract can also be used. Briefly, a solution
of the product at about 100 .mu.g/ml is serially two-fold diluted
in 50 mM Tris-HCl (pH 7.5). 100 .mu.l of each dilution are applied
to a nitrocellulose membrane 0.45 .mu.m set in a 96-well dot blot
apparatus (Biorad). The buffer is removed by applying vacuum to the
system. Wells are washed by addition of 50 mM Tris-HCl (pH 7.5) and
the membrane is air-dried. The membrane is saturated in blocking
buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10 g/L skim milk) and
incubated with an antiserum dilution from about 1:50 to about
1:5000, preferably about 1:500. The reaction is revealed according
to standard procedures. For example, a goat anti-rabbit peroxidase
conjugate is added to the wells when rabbit antibodies are used.
Incubation is carried out 90 minutes at 37.degree. C. and the blot
is washed. The reaction is developed with the appropriate substrate
and stopped. The reaction is measured visually by the appearance of
a colored spot, e.g., by colorimetry. Under the above experimental
conditions, a positive reaction is shown once a colored spot is
associated with a dilution of at least about 1:5, preferably of at
least about 1:500.
[0110] Therapeutic or prophylactic efficacy of a polypeptide or
derivative of the invention can be evaluated as described below. A
seventh aspect of the invention provides (i) a composition of
matter comprising a polypeptide of the invention together with a
diluent or carrier; specifically (ii) a pharmaceutical composition
containing a therapeutically or prophylactically effective amount
of a polypeptide of the invention; (iii) a method for inducing an
immune response against Chlamydia in a mammal, by administering to
the mammal an immunogenically effective amount of a polypeptide of
the invention to elicit a protective immune response to Chlamydia;
and particularly, (iv) a method for preventing and/or treating a
Chlamydia (e.g., C. trachomatis. C. psittaci, C. pneumoniae. or C.
pecorum) infection, by administering a prophylactic or therapeutic
amount of a polypeptide of the invention to an infected individual.
Additionally, the seventh aspect of the invention encompasses the
use of a polypeptide of the invention in the preparation of a
medicament for preventing and/or treating Chlamydia infection.
[0111] As used herein, the immunogenic compositions of the
invention are administered by conventional routes known the vaccine
field, in particular to a mucosal (e.g., ocular, intranasal,
pulmonary, oral, gastric, intestinal, rectal, vaginal, or urinary
tract) surface or via the parenteral (e.g., subcutaneous,
intradermal, intramuscular, intravenous, or intraperitoneal) route.
The choice of administration route depends upon a number of
parameters, such as the adjuvant associated with the polypeptide.
If a mucosal adjuvant is used, the intranasal or oral route is
preferred. If a lipid formulation or an aluminum compound is used,
the parenteral route is preferred with the sub-cutaneous or
intramuscular route being most preferred. The choice also depends
upon the nature of the vaccine agent. For example, a polypeptide of
the invention fused to CTB or LTB is best administered to a mucosal
surface.
[0112] As used herein, the composition of the invention contains
one or several polypeptides or derivatives of the invention. The
composition optionally contains at least one additional Chlamydia
antigen, or a subunit, fragment, homolog, mutant, or derivative
thereof.
[0113] For use in a composition of the invention, a polypeptide or
derivative thereof is formulated into or with liposomes, preferably
neutral or anionic liposomes, microspheres, ISCOMS, or
virus-like-particles (VLPs) to facilitate delivery and/or enhance
the immune response. These compounds are readily available to one
skilled in the art; for example, see Liposomes: A Practical
Approach, RCP New Ed, IRL press (1990).
[0114] Adjuvants other than liposomes and the like are also used
and are known in the art. Adjuvants may protect the antigen from
rapid dispersal by sequestering it in a local deposit, or they may
contain substances that stimulate the host to secrete factors that
are chemotactic for macrophages and other components of the immune
system. An appropriate selection can conventionally be made by
those skilled in the art, for example, from those described below
(under the eleventh aspect of the invention).
[0115] Treatment is achieved in a single dose or repeated as
necessary at intervals, as can be determined readily by one skilled
in the art. For example, a priming dose is followed by three
booster doses at weekly or monthly intervals. An appropriate dose
depends on various parameters including the recipient (e.g., adult
or infant), the particular vaccine antigen, the route and frequency
of administration, the presence/absence or type of adjuvant, and
the desired effect (e.g., protection and/or treatment), as can be
determined by one skilled in the art. In general, a vaccine antigen
of the invention is administered by a mucosal route in an amount
from about 10 .mu.g to about 500 mg, preferably from about 1 mg to
about 200 mg. For the parenteral route of administration, the dose
usually does not exceed about 1 mg, preferably about 100 .mu.g.
[0116] When used as vaccine agents, polynucleotides and
polypeptides of the invention may be used sequentially as part of a
multistep immunization process. For example, a mammal is initially
primed with a vaccine vector of the invention such as a pox virus,
e.g., via the parenteral route, and then boosted twice with the
polypeptide encoded by the vaccine vector, e.g., via the mucosal
route. In another example, liposomes associated with a polypeptide
or derivative of the invention is also used for priming, with
boosting being carried out mucosally using a soluble polypeptide or
derivative of the invention in combination with a mucosal adjuvant
(e.g., LT).
[0117] A polypeptide derivative of the invention is also used in
accordance with the seventh aspect as a diagnostic reagent for
detecting the presence of anti-Chlamydia antibodies, e.g., in a
blood sample. Such polypeptides are about 5 to about 80, preferably
about 10 to about 50 amino acids in length. They are either labeled
or unlabeled, depending upon the diagnostic method. Diagnostic
methods involving such a reagent are described below.
[0118] Upon expression of a DNA molecule of the invention, a
polypeptide or polypeptide derivative is produced and purified
using known laboratory techniques. As described above, the
polypeptide or polypeptide derivative may be produced as a fusion
protein containing a fused tail that facilitates purification. The
fusion product is used to immunize a small mammal, e.g., a mouse or
a rabbit, in order to raise antibodies against the polypeptide or
polypeptide derivative (monospecific antibodies). Accordingly, an
eighth aspect of the invention provides a monospecific antibody
that binds to a polypeptide or polypeptide derivative of the
invention.
[0119] By "monospecific antibody" is meant an antibody that is
capable of reacting with a unique naturally-occurring Chlamydia
polypeptide. An antibody of the invention is either polyclonal or
monoclonal. Monospecific antibodies may be recombinant, e.g.,
chimeric (e.g., constituted by a variable region of murine origin
associated with a human constant region), humanized (a human
immunoglobulin constant backbone together with hypervariable region
of animal, e.g., murine, origin), and/or single chain. Both
polyclonal and monospecific antibodies may also be in the form of
immunoglobulin fragments, e.g., F(ab)'2 or Fab fragments. The
antibodies of the invention are of any isotype, e.g., IgG or IgA,
and polyclonal antibodies are of a single isotype or a mixture of
isotypes.
[0120] Antibodies against the polypeptides, homologs or fragments
of the present invention are generated by immunization of a mammal
with a composition comprising said polypeptide, homolog or
fragment. Such antibodies may be polyclonal or monoclonal. Methods
to produce polyclonal or monoclonal antibodies are well known in
the art. For a review, see "Antibodies, A Laboratory Manual, Cold
Spring Harbor Laboratory, Eds. E. Harlow and D. Lane (1988), and D.
E. Yelton et al., 1981. Ann. Rev. Biochem. 50:657-680. For
monoclonal antibodies, see Kohler & Milstein (1975) Nature
256:495-497.
[0121] The antibodies of the invention, which are raised to a
polypeptide or polypeptide derivative of the invention, are
produced and identified using standard immunological assays, e.g.,
Western blot analysis, dot blot assay, or ELISA (see, e.g., Coligan
et al., Current Protocols in Immunology (1994) John Wiley &
Sons, Inc., New York, N.Y.). The antibodies are used in diagnostic
methods to detect the presence of a Chlamydia antigen in a sample,
such as a biological sample. The antibodies are also used in
affinity chromatography for purifying a polypeptide or polypeptide
derivative of the invention. As is discussed further below, such
antibodies may be used in prophylactic and therapeutic passive
immunization methods.
[0122] Accordingly, a ninth aspect of the invention provides (i) a
reagent for detecting the presence of Chlamydia in a biological
sample that contains an antibody, polypeptide, or polypeptide
derivative of the invention; and (ii) a diagnostic method for
detecting the presence of Chlamydia in a biological sample, by
contacting the biological sample with an antibody, a polypeptide,
or a polypeptide derivative of the invention, such that an immune
complex is formed, and by detecting such complex to indicate the
presence of Chlamydia in the sample or the organism from which the
sample is derived.
[0123] Those skilled in the art will readily understand that the
immune complex is formed between a component of the sample and the
antibody, polypeptide, or polypeptide derivative, whichever is
used, and that any unbound material is removed prior to detecting
the complex. It is understood that a polypeptide reagent is useful
for detecting the presence of anti-Chlamydia antibodies in a
sample, e.g., a blood sample, while an antibody of the invention is
used for screening a sample, such as a gastric extract or biopsy,
for the presence of Chlamydia polypeptides.
[0124] For diagnostic applications, the reagent (i.e., the
antibody, polypeptide, or polypeptide derivative of the invention)
is either in a free state or immobilized on a solid support, such
as a tube, a bead, or any other conventional support used in the
field. Immobilization is achieved using direct or indirect means.
Direct means include passive adsorption (non-covalent binding) or
covalent binding between the support and the reagent. By "indirect
means" is meant that an anti-reagent compound that interacts with a
reagent is first attached to the solid support. For example, if a
polypeptide reagent is used, an antibody that binds to it can serve
as an anti-reagent, provided that it binds to an epitope that is
not involved in the recognition of antibodies in biological
samples. Indirect means may also employ a ligand-receptor system,
for example, where a molecule such as a vitamin is grafted onto the
polypeptide reagent and the corresponding receptor immobilized on
the solid phase. This is illustrated by the biotin-streptavidin
system. Alternatively, a peptide tail is added chemically or by
genetic engineering to the reagent and the grafted or fused product
immobilized by passive adsorption or covalent linkage of the
peptide tail.
[0125] Such diagnostic agents may be included in a kit which also
comprises instructions for use. The reagent is labeled with a
detection means which allows for the detection of the reagent when
it is bound to its target. The detection means may be a fluorescent
agent such as fluorescein isocyanate or fluorescein isothiocyanate,
or an enzyme such as horse radish peroxidase or luciferase or
alkaline phosphatase, or a radioactive element such as .sup.125I or
.sup.51Cr.
[0126] Accordingly, a tenth aspect of the invention provides a
process for purifying, from a biological sample, a polypeptide or
polypeptide derivative of the invention, which involves carrying
out antibody-based affinity chromatography with the biological
sample, wherein the antibody is a monospecific antibody of the
invention.
[0127] For use in a purification process of the invention, the
antibody is either polyclonal or monospecific, and preferably is of
the IgG type. Purified IgGs is prepared from an antiserum using
standard methods (see, e.g., Coligan et al., Current Protocols in
Immunology (1994) John Wiley & Sons, Inc., New York, N.Y.).
Conventional chromatography supports, as well as standard methods
for grafting antibodies, are described in, e.g., Antibodies: A
Laboratory Manual, D. Lane, E. Harlow, Eds. (1988) and outlined
below.
[0128] Briefly, a biological sample, such as an C. pneumoniae
extract preferably in a buffer solution, is applied to a
chromatography material, preferably equilibrated with the buffer
used to dilute the biological sample so that the polypeptide or
polypeptide derivative of the invention (i.e., the antigen) is
allowed to adsorb onto the material. The chromatography material,
such as a gel or a resin coupled to an antibody of the invention,
is in either a batch form or a column. The unbound components are
washed off and the antigen is then eluted with an appropriate
elution buffer, such as a glycine buffer or a buffer containing a
chaotropic agent, e.g., guanidine HCl, or high salt concentration
(e.g., 3 M MgCl.sub.2). Eluted fractions are recovered and the
presence of the antigen is detected, e.g., by measuring the
absorbance at 280 nm.
[0129] An eleventh aspect of the invention provides (i) a
composition of matter comprising a monospecific antibody of the
invention, together with a diluent or carrier; (ii) a
pharmaceutical composition comprising a therapeutically or
prophylactically effective amount of a monospecific antibody of the
invention, and (iii) a method for treating or preventing a
Chlamydia (e.g., C. trachomatis, C. psittaci, C. pneumoniae or C.
pecorum) infection, by administering a therapeutic or prophylactic
amount of a monospecific antibody of the invention to an infected
individual. Additionally, the eleventh aspect of the invention
encompasses the use of a monospecific antibody of the invention in
the preparation of a medicament for treating or preventing
Chlamydia infection.
[0130] The monospecific antibody is either polyclonal or
monoclonal, preferably of the IgA isotype (predominantly). In
passive immunization, the antibody is administered to a mucosal
surface of a mammal, e.g., the gastric mucosa, e.g., orally or
intragastrically, advantageously, in the presence of a bicarbonate
buffer. Alternatively, systemic administration, not requiring a
bicarbonate buffer, is carried out. A monospecific antibody of the
invention is administered as a single active component or as a
mixture with at least one monospecific antibody specific for a
different Chlamydia polypeptide. The amount of antibody and the
particular regimen used are readily determined by one skilled in
the art. For example, daily administration of about 100 to 1,000 mg
of antibodies over one week, or three doses per day of about 100 to
1,000 mg of antibodies over two or three days, are effective
regimens for most purposes.
[0131] Therapeutic or prophylactic efficacy are evaluated using
standard methods in the art, e.g., by measuring induction of a
mucosal immune response or induction of protective and/or
therapeutic immunity, using, e.g., the C. pneumoniae mouse model.
Those skilled in the art will readily recognize that the C.
pneumoniae strain of the model may be replaced with another
Chlamydia strain. For example, the efficacy of DNA molecules and
polypeptides from C. pneumoniae is preferably evaluated in a mouse
model using C. pneumoniae strain. Protection is determined by
comparing the degree of Chlamydia infection to that of a control
group. Protection is shown when infection is reduced by comparison
to the control group. Such an evaluation is made for
polynucleotides, vaccine vectors, polypeptides and derivatives
thereof, as well as antibodies of the invention.
[0132] Adjuvants useful in any of the vaccine compositions
described above are as follows.
[0133] Adjuvants for parenteral administration include aluminum
compounds, such as aluminum hydroxide, aluminum phosphate, and
aluminum hydroxy phosphate. The antigen is precipitated with, or
adsorbed onto, the aluminum compound according to standard
protocols. Other adjuvants, such as RIBI (ImmunoChem, Hamilton,
Mont.), are used in parenteral administration.
[0134] Adjuvants for mucosal administration include bacterial
toxins, e.g., the cholera toxin (CT), the E. coli heat-labile toxin
(LT), the Clostridium difficile toxin A and the pertussis toxin
(PT), or combinations, subunits, toxoids, or mutants thereof such
as a purified preparation of native cholera toxin subunit B (CTB).
Fragments, homologs, derivatives, and fusions to any of these
toxins are also suitable, provided that they retain adjuvant
activity. Preferably, a mutant having reduced toxicity is used.
Suitable mutants are described, e.g., in WO 95/17211 (Arg-7-Lys CT
mutant), WO 96/06627 (Arg-192-Gly LT mutant), and WO 95/34323
(Arg-9-Lys and Glu-129-Gly PT mutant). Additional LT mutants that
are used in the methods and compositions of the invention include,
e.g., Ser-63-Lys, Ala-69Gly, Glu-110-Asp, and Glu-112-Asp mutants.
Other adjuvants, such as a bacterial monophosphoryl lipid A (MPLA)
of, e.g., E. coli, Salmonella minnesota, Salmonella typhimurium, or
Shigella flexneri; saponins, or polylactide glycolide (PLGA)
microspheres, is also be used in mucosal administration.
[0135] Adjuvants useful for both mucosal and parenteral
administrations include polyphosphazene (WO 95/02415), DC-chol (3
b-(N--(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol; U.S.
Pat. No. 5,283,185 and WO 96/14831) and QS-21 (WO 88/09336).
[0136] Any pharmaceutical composition of the invention containing a
polynucleotide, a polypeptide, a polypeptide derivative, or an
antibody of the invention, is manufactured in a conventional
manner. In particular, it is formulated with a pharmaceutically
acceptable diluent or carrier, e.g., water or a saline solution
such as phosphate buffer saline. In general, a diluent or carrier
is selected on the basis of the mode and route of administration,
and standard pharmaceutical practice. Suitable pharmaceutical
carriers or diluents, as well as pharmaceutical necessities for
their use in pharmaceutical formulations, are described in
Remington's Pharmaceutical Sciences, a standard reference text in
this field and in the USP/NF.
[0137] The invention also includes methods in which Chlamydia
infection are treated by oral administration of a Chlamydia
polypeptide of the invention and a mucosal adjuvant, in combination
with an antibiotic, an antacid, sucralfate, or a combination
thereof. Examples of such compounds that can be administered with
the vaccine antigen and the adjuvant are antibiotics, including,
e.g., macrolides, tetracyclines, and derivatives thereof (specific
examples of antibiotics that can be used include azithromycin or
doxicyclin or immunomodulators such as cytokines or steroids). In
addition, compounds containing more than one of the above-listed
components coupled together, are used. The invention also includes
compositions for carrying out these methods, i.e., compositions
containing a Chlamydia antigen (or antigens) of the invention, an
adjuvant, and one or more of the above-listed compounds, in a
pharmaceutically acceptable carrier or diluent.
[0138] It has recently been shown that the 60 kDa cysteine rich
membrane protein contains a sequence cross-reactive with the murine
alpha-myosin heavy chain epitope M7A-alpha, an epitope conserved in
humans (Bachmaier et al., Science (1999) 283:1335). This
cross-reactivity is proposed to contribute to the development of
cardiovascular disease, so it may be beneficial to remove this
epitope, and any other epitopes cross-reactive with human antigens,
from the protein if it is to be used as a vaccine. Accordingly, a
further embodiment of the present invention includes the
modification of the coding sequence, for example, by deletion or
substitution of the nucleotides encoding the epitope from
polynucleotides encoding the protein, as to improve the efficacy
and safety of the protein as a vaccine. A similar approach may be
appropriate for any protective antigen found to have unwanted
homologies or cross-reactivities with human antigens.
[0139] Amounts of the above-listed compounds used in the methods
and compositions of the invention are readily determined by one
skilled in the art.
[0140] Treatment/immunization schedules are also known and readily
designed by one skilled in the art. For example, the non-vaccine
components can be administered on days 1-14, and the vaccine
antigen+adjuvant can be administered on days 7, 14, 21, and 28.
EXAMPLES
[0141] The above disclosure generally describes the present
invention. A more complete understanding can be obtained by
reference to the following specific examples. These examples are
described solely for purposes of illustration and are not intended
to limit the scope of the invention. Changes in form and
substitution of equivalents are contemplated as circumstances may
suggest or render expedient. Although specific terms have been
employed herein, such terms are intended in a descriptive sense and
not for purposes of limitation.
Example 1
[0142] This example illustrates the preparation of plasmid vector
pCABk831 containing the omp P6 precursor gene.
[0143] The omp P6 precursor gene (SEQ ID No:1) was amplified from
Chlamydia pneumoniae genomic DNA by polymerase chain reaction (PCR)
using a 5' primer (5' ATAAGAATGCGGCCGCCACCATGAATATACATTCCCTATGGAAAC
3'; SEQ ID No:3) and a 3' primer (5'
GCGCCGGATCCCGCGTGCATGAATCTTAAACTCTGTACGGC 3'; SEQ ID No:4). The 5'
primer contains a NotI restriction site, a ribosome binding site,
an initiation codon and a sequence at the 5' end of the omp P6
precursor coding sequence. The 3' primer includes the sequence
encoding the C-terminal sequence of the omp P6 precursor gene and a
BamHI restriction site. The stop codon was excluded and an
additional nucleotide was inserted to obtain an in-frame fusion
with the Histidine tag.
[0144] After amplification, the PCR fragment was purified using
QIAquick.TM. PCR purification kit (Qiagen), digested with NotI and
BamHI and cloned into the pCA-Myc-His eukaryotic expression vector
described in Example 2 (FIG. 3) with transcription under control of
the human CMV promoter.
Example 2
[0145] This example illustrates the preparation of the eukaryotic
expression vector pCA/Myc-His.
[0146] Plasmid pcDNA3.1(-)Myc-His C (Invitrogen) was restricted
with SpeI and BamHI to remove the CMV promoter and the remaining
vector fragment was isolated. The CMV promoter and intron A from
plasmid VR-1012 (Vical) was isolated on a SpeI/BamHI fragment. The
fragments were ligated together to produce plasmid pCA/Myc-His. The
NotI/BamHI restricted PCR fragment containing the omp P6 precursor
gene (SEQ ID No:1) was ligated into the NotI and BamHI restricted
plasmid pCA/Myc-His to produce plasmid pCABk831 (FIG. 3).
[0147] The resulting plasmid, pCABk831, was transferred by
electroporation into E. coli XL-1 blue (Stratagene) which was grown
in LB broth containing 50 .mu.g/ml carbenicillin. The plasmid was
isolated by the Endo Free Plasmid Giga Kit.TM. (Qiagen) large scale
DNA purification system. DNA concentration was determined by
absorbance at 260 nm and the plasmid was verified after gel
electrophoresis and ethidium bromide staining by comparison to
molecular weight standards. The 5' and 3' ends of the gene were
verified by sequencing using a LiCor model 4000 L DNA sequencer and
IRD-800 labelled primers.
Example 3
[0148] This example illustrates the immunization of mice to achieve
protection against an intranasal challenge of C. pneumoniae.
[0149] It has been previously demonstrated (Yang et al. Infect.
Immun. May 1993. 61(5):2037-40) that mice are susceptible to
intranasal infection with different isolates of C. pneumoniae.
Strain AR-39 (Grayston et al (1990) Journal of Infectious Diseases
161:618-625) was used in Balb/c mice as a challenge infection model
to examine the capacity of Chlamydia gene products delivered as
naked DNA to elicit a protective response against a sublethal C.
pneumoniae lung infection. Protective immunity is defined as an
accelerated clearance of pulmonary infection.
[0150] Groups of 7 to 9 week old male Balb/c mice (8 to 10 per
group) were immunized intramuscularly (i.m.) plus intranasally
(i.n.) with plasmid DNA containing the C. pneumoniae omp P6
precursor gene as described in Examples 1 and 2. Saline or the
plasmid vector lacking an inserted Chlamydial gene was given to
groups of control animals.
[0151] For i.m. immunization, alternate left and right quadriceps
were injected with 100 .mu.g of DNA in 50 .mu.l of PBS on three
occasions at 0, 3 and 6 weeks. For i.n. immunization, anaesthetized
mice were aspirated 50 .mu.l of PBS containing 50 .mu.g DNA on
three occasions at 0, 3 and 6 weeks. At week 8, immunized mice were
inoculated i.n. with 5.times.10.sup.5 IFU of C. pneumoniae, strain
AR39 in 100 .mu.l of SPG buffer to test their ability to limit the
growth of a sublethal C. pneumoniae challenge.
[0152] Lungs were taken from mice at day 9 post-challenge and
immediately homogenised in SPG buffer (7.5% sucrose, 5 mM
glutamate, 12.5 mM phosphate pH7.5). The homogenate was stored
frozen at -70.degree. C. until assay. Dilutions of the homogenate
were assayed for the presence of infectious Chlamydia by
inoculation onto monolayers of susceptible cells. The inoculum was
centrifuged onto the cells at 3000 rpm for 1 hour, then the cells
were incubated for three days at 35.degree. C. in the presence of 1
.mu.g/ml cycloheximide. After incubation the monolayers were fixed
with formalin and methanol then immunoperoxidase stained for the
presence of Chlamydial inclusions using convalescent sera from
rabbits infected with C. pneumoniae and metal-enhanced DAB as a
peroxidase substrate.
[0153] FIG. 4 and Table 1 show that mice immunized i.n. and i.m.
with pCABk831 had Chlamydial lung titers less than 39,500 in 5 of 6
cases at day 9 (mean 24,933) whereas the range of values for
control mice sham immunized with saline was 13,500 to 178,700
IFU/lung (mean 69,782) at day 9. DNA immunisation per se was not
responsible for the observed protective effect since another
plasmid DNA construct, pCABk1106, failed to protect, with lung
titers in immunised mice similar to those obtained for
saline-immunized control mice (mean 62,516). The construct
pCABk1106 is identical to pCABk831 except that the nucleotide
sequence encoding the putative omp P6 precursor is replaced with a
C. pneumoniae nucleotide sequence encoding an unrelated
hypothetical protein.
TABLE-US-00001 TABLE 1 BACTERIAL LOAD (INCLUSION FORMING UNITS PER
LUNG) IN THE LUNGS OF BALB/C MICE IMMUNIZED WITH VARIOUS DNA
IMMUNIZATION CONSTRUCTS IMMUNIZING CONSTRUCT Saline pCABk1106
pCABk831 MOUSE Day 9 Day 9 Day 9 1 17300 137900 39100 2 88800 43700
68200 3 90000 105200 3300 4 44500 45800 11800 5 156500 27600 8300 6
69700 14900 18900 7 13500 8 14100 9 71700 10 103000 11 112100 12
59500 13 90200 14 178700 15 55400 16 23800 17 66700 18 66800 19
53800 20 38700 21 127000 22 28000 23 35200 24 78900 MEAN 69782.61
62516.67 24933.33 SD 44216.7 48217.32 24601.84 Wilcoxon p 0.6594
0.0119
Sequence CWU 1
1
41779DNAChlamydia pneumoniaeCDS(101)..(676) 1gtctagtcac caaaaaaact
aacaaaattg ctataggagt aggagaaaaa cggttcccct 60cctggggtgc tttccctcag
caaccgataa agagaacact atg aat ata cat tcc 115 Met Asn Ile His Ser 1
5cta tgg aaa ctt tgt act tta ttg gct tta ctt gca ttg cca gca tgt
163Leu Trp Lys Leu Cys Thr Leu Leu Ala Leu Leu Ala Leu Pro Ala Cys
10 15 20agc ctt tcc cct aat tat ggc tgg gag gat tcc tgt aat aca tgc
cat 211Ser Leu Ser Pro Asn Tyr Gly Trp Glu Asp Ser Cys Asn Thr Cys
His 25 30 35cat aca aga cga aaa aag cct tct tct ttt ggc ttt gtt cct
ctc tat 259His Thr Arg Arg Lys Lys Pro Ser Ser Phe Gly Phe Val Pro
Leu Tyr 40 45 50acc gaa gag gac ttt aac cct aat ttt acc ttc ggt gag
tat gat tcc 307Thr Glu Glu Asp Phe Asn Pro Asn Phe Thr Phe Gly Glu
Tyr Asp Ser 55 60 65aaa gaa gaa aaa caa tac aag tca agc caa gtt gca
gca ttt cgt aat 355Lys Glu Glu Lys Gln Tyr Lys Ser Ser Gln Val Ala
Ala Phe Arg Asn70 75 80 85atc acc ttt gct aca gac agc tat aca att
aaa ggt gaa gag aac ctt 403Ile Thr Phe Ala Thr Asp Ser Tyr Thr Ile
Lys Gly Glu Glu Asn Leu 90 95 100gcg att ctc acg aac ttg gtt cac
tac atg aag aaa aac ccg aaa gct 451Ala Ile Leu Thr Asn Leu Val His
Tyr Met Lys Lys Asn Pro Lys Ala 105 110 115aca ctg tac att gaa ggg
cat act gac gag cgt gga gct gca tcc tat 499Thr Leu Tyr Ile Glu Gly
His Thr Asp Glu Arg Gly Ala Ala Ser Tyr 120 125 130aac ctt gct tta
gga gca cga cga gcc aat gcg att aaa gag cat ctc 547Asn Leu Ala Leu
Gly Ala Arg Arg Ala Asn Ala Ile Lys Glu His Leu 135 140 145cga aag
cag gga atc tct gca gat cgt cta tct act att tcc tac gga 595Arg Lys
Gln Gly Ile Ser Ala Asp Arg Leu Ser Thr Ile Ser Tyr Gly150 155 160
165aaa gaa cat cct tta aat tcg gga cac aac gaa cta gca tgg caa caa
643Lys Glu His Pro Leu Asn Ser Gly His Asn Glu Leu Ala Trp Gln Gln
170 175 180aat cgc cgt aca gag ttt aag att cat gca cgc taagctaagc
ttttttattc 696Asn Arg Arg Thr Glu Phe Lys Ile His Ala Arg 185
190ttctaagtct gttattttca ggaatagatt gcagtcgttt gcatgctgct
ggaaggtctc 756cttctctaca aggagtcctt gca 7792192PRTChlamydia
pneumoniae 2Met Asn Ile His Ser Leu Trp Lys Leu Cys Thr Leu Leu Ala
Leu Leu1 5 10 15Ala Leu Pro Ala Cys Ser Leu Ser Pro Asn Tyr Gly Trp
Glu Asp Ser 20 25 30Cys Asn Thr Cys His His Thr Arg Arg Lys Lys Pro
Ser Ser Phe Gly 35 40 45Phe Val Pro Leu Tyr Thr Glu Glu Asp Phe Asn
Pro Asn Phe Thr Phe 50 55 60Gly Glu Tyr Asp Ser Lys Glu Glu Lys Gln
Tyr Lys Ser Ser Gln Val65 70 75 80Ala Ala Phe Arg Asn Ile Thr Phe
Ala Thr Asp Ser Tyr Thr Ile Lys 85 90 95Gly Glu Glu Asn Leu Ala Ile
Leu Thr Asn Leu Val His Tyr Met Lys 100 105 110Lys Asn Pro Lys Ala
Thr Leu Tyr Ile Glu Gly His Thr Asp Glu Arg 115 120 125Gly Ala Ala
Ser Tyr Asn Leu Ala Leu Gly Ala Arg Arg Ala Asn Ala 130 135 140Ile
Lys Glu His Leu Arg Lys Gln Gly Ile Ser Ala Asp Arg Leu Ser145 150
155 160Thr Ile Ser Tyr Gly Lys Glu His Pro Leu Asn Ser Gly His Asn
Glu 165 170 175Leu Ala Trp Gln Gln Asn Arg Arg Thr Glu Phe Lys Ile
His Ala Arg 180 185 190345DNAArtificial Sequence5' PCR primer
3ataagaatgc ggccgccacc atgaatatac attccctatg gaaac
45441DNAArtificial Sequence3' PCR primer 4gcgccggatc ccgcgtgcat
gaatcttaaa ctctgtacgg c 41
* * * * *